OncoMed Pharmaceuticals Inc. presented new data from the Phase 1b clinical trial of demcizumab in patients with first-line advanced non-small cell lung cancer at the European Lung Cancer Conference. Demcizumab is a first-in-class monoclonal antibody targeting DLL4 with anti-cancer stem cell, dysangiogenesis and potential immune modulatory properties.
http://ift.tt/1CPxcuV
http://ift.tt/1CPxcuV
No comments:
Post a Comment